• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国肾移植受者移植后恶性肿瘤的流行病学:单中心经验及文献综述

Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review.

作者信息

Zhang Jian, Ma Linlin, Xie Zelin, Guo Yuwen, Sun Wen, Zhang Lei, Lin Jun, Xiao Jing, Zhu Yichen, Tian Ye

机构信息

Department of Urology, Beijing Friendship Hospital Affiliated to Capital Medical University, No. 95 Yongan Road, Xicheng District, Beijing, 100050, China.

出版信息

Med Oncol. 2014 Jul;31(7):32. doi: 10.1007/s12032-014-0032-6. Epub 2014 Jun 8.

DOI:10.1007/s12032-014-0032-6
PMID:24908063
Abstract

This study investigated the incidence and types of post-transplant malignancy in Chinese renal transplant recipients and the risk factors associated with malignancy. Data from 3,462 patients who underwent renal transplantation at Beijing Friendship Hospital were combined with data from 26 previous reports describing malignancy rates in 27,170 Chinese renal transplant recipients. Between 1974 and 2014, 179/3,462 (5.17 %) patients who underwent renal transplantation at our center developed malignancy. The most common site of malignancy was the urinary system, and the most common type was urothelial transitional cell carcinoma. Combined data from our center and previous reports showed malignancy in 671 (2.19 %) Chinese renal transplant recipients. The ten most common malignancies were urothelial transitional cell carcinoma (n = 283), hepatocellular carcinoma (n = 68), gastrointestinal cancer (n = 63), renal cell carcinoma (n = 42), lymphoma (n = 42), lung cancer (n = 28), breast cancer (n = 19), skin cancer (n = 18), Kaposi's sarcoma (n = 12), and cervical cancer (n = 10). The incidence of post-transplant malignancy in renal transplant recipients was lower in China than the reported rates in other countries, and the most common sites of malignancy were the urinary and digestive system. The relative frequency of malignancy sites differed between northern and southern China. Renal transplant recipients on long-term immunosuppressive therapy should receive careful follow-up, including annual or biannual screening for malignancy in high-risk individuals.

摘要

本研究调查了中国肾移植受者移植后恶性肿瘤的发病率、类型以及与恶性肿瘤相关的危险因素。将北京友谊医院3462例接受肾移植患者的数据与之前26篇描述27170例中国肾移植受者恶性肿瘤发生率的报告数据相结合。1974年至2014年期间,在我们中心接受肾移植的患者中有179/3462例(5.17%)发生了恶性肿瘤。恶性肿瘤最常见的部位是泌尿系统,最常见的类型是尿路上皮移行细胞癌。我们中心和既往报告的综合数据显示,671例(2.19%)中国肾移植受者发生了恶性肿瘤。十种最常见的恶性肿瘤为尿路上皮移行细胞癌(n = 283)、肝细胞癌(n = 68)、胃肠道癌(n = 63)、肾细胞癌(n = 42)、淋巴瘤(n = 42)、肺癌(n = 28)、乳腺癌(n = 19)、皮肤癌(n = 18)、卡波西肉瘤(n = 12)和宫颈癌(n = 10)。中国肾移植受者移植后恶性肿瘤的发病率低于其他国家报告的发病率,恶性肿瘤最常见的部位是泌尿系统和消化系统。中国北方和南方恶性肿瘤的发病部位相对频率有所不同。长期接受免疫抑制治疗的肾移植受者应接受仔细随访,包括对高危个体每年或每半年进行一次恶性肿瘤筛查。

相似文献

1
Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review.中国肾移植受者移植后恶性肿瘤的流行病学:单中心经验及文献综述
Med Oncol. 2014 Jul;31(7):32. doi: 10.1007/s12032-014-0032-6. Epub 2014 Jun 8.
2
Malignancy following renal transplantation.肾移植后的恶性肿瘤
Zhonghua Yi Xue Za Zhi (Taipei). 1998 May;61(5):281-8.
3
Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience.肾移植受者移植后恶性肿瘤的不同发病时间:单中心经验
Transpl Int. 2009 Jun;22(6):644-53. doi: 10.1111/j.1432-2277.2009.00846.x. Epub 2009 Feb 10.
4
Special malignancy pattern in Chinese renal transplantation recipients: a single center experience and literature review.中国肾移植受者的特殊恶性肿瘤模式:单中心经验及文献综述
Asian Pac J Cancer Prev. 2011;12(12):3347-51.
5
Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.单中心674例实体器官移植受者的移植后恶性肿瘤发病率。
Clin Transplant. 1996 Jun;10(3):248-55.
6
The benefits of cancer screening in kidney transplant recipients: a single-center experience.肾移植受者癌症筛查的益处:单中心经验
Cancer Med. 2016 Feb;5(2):153-8. doi: 10.1002/cam4.568. Epub 2015 Dec 21.
7
Risk Factors and Incidence of Malignancy After Kidney Transplant in Mainland China: A Single-Center Analysis.中国大陆肾移植后恶性肿瘤的发病风险因素和发生率:单中心分析。
Exp Clin Transplant. 2022 Jun;20(6):558-563. doi: 10.6002/ect.2022.0087.
8
De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.台湾地区心、肾、肝移植后新发恶性肿瘤:一项全国性研究。
Exp Clin Transplant. 2020 Apr;18(2):224-233. doi: 10.6002/ect.2019.0210. Epub 2020 Mar 4.
9
Distinguishing characteristics of urothelial carcinoma in kidney transplant recipients between China and Western countries.中国与西方国家肾移植受者尿路上皮癌的鉴别特征。
Transplant Proc. 2013 Jul-Aug;45(6):2197-202. doi: 10.1016/j.transproceed.2012.10.035. Epub 2013 Jun 6.
10
Incidence and Risk Factors of Post-renal Transplantation Malignancies in North of Iran, A 20-year Experience.伊朗北部肾移植后恶性肿瘤的发病率和危险因素:20 年经验。
Iran J Kidney Dis. 2020 Dec;14(6):439-447.

引用本文的文献

1
Risk of malignant neoplasms of tacrolimus in kidney transplant patients: a retrospective cohort study conducted using the Japanese National Database of Health Insurance Claims.肾移植患者中他克莫司导致恶性肿瘤的风险:一项使用日本全国健康保险理赔数据库进行的回顾性队列研究。
BMC Nephrol. 2025 Aug 26;26(1):491. doi: 10.1186/s12882-025-04405-8.
2
Uncovering the Risk: Incidence of Upper Tract Urothelial Carcinoma Following Renal Transplantation in the Netherlands.揭示风险:荷兰肾移植术后上尿路尿路上皮癌的发病率
Eur Urol Open Sci. 2025 Apr 16;76:1-6. doi: 10.1016/j.euros.2025.03.004. eCollection 2025 Jun.
3
Incidence, Risk Factors, and Outcomes of De Novo Malignancy following Kidney Transplantation.

本文引用的文献

1
Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong Renal Registry.肾移植后肝细胞癌:香港肾脏登记处分析
Ren Fail. 2014 Jul;36(6):865-9. doi: 10.3109/0886022X.2014.899879. Epub 2014 Mar 24.
2
Annual report on status of cancer in China, 2010.《中国癌症报告 2010》年度报告
Chin J Cancer Res. 2014 Feb;26(1):48-58. doi: 10.3978/j.issn.1000-9604.2014.01.08.
3
Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy.根治性肾输尿管切除术后上尿路尿路上皮癌膀胱复发的风险分层
肾移植后新发恶性肿瘤的发病率、危险因素及预后
J Clin Med. 2024 Mar 24;13(7):1872. doi: 10.3390/jcm13071872.
4
Current Trends and Future Directions of Malignancy After kidney Transplantation: A 1970-2022 Bibliometric Analysis.当前肾移植后恶性肿瘤的趋势和未来方向:1970-2022 年文献计量分析。
Ann Transplant. 2024 Jan 2;29:e942074. doi: 10.12659/AOT.942074.
5
Prolonged Survival and Preserved Renal Graft Function in a Kidney Transplant Patient With Advanced Urothelial Carcinoma Using an Immune Checkpoint Inhibitor: A Case Report.使用免疫检查点抑制剂治疗晚期尿路上皮癌的肾移植患者的长期生存及保留肾移植功能:一例报告
Transplant Direct. 2023 Jun 28;9(7):e1509. doi: 10.1097/TXD.0000000000001509. eCollection 2023 Jul.
6
Clinical characteristics and treatment outcomes of kidney transplant recipients with de novo urothelial carcinoma: thirty years of experience from a single center.肾移植受者新发尿路上皮癌的临床特征和治疗结局:单中心 30 年经验。
BMC Urol. 2023 Apr 28;23(1):71. doi: 10.1186/s12894-023-01232-7.
7
De novo upper tract urothelial carcinoma after renal transplantation: a single-center experience in China.肾移植后新发上尿路尿路上皮癌:中国单中心经验。
BMC Urol. 2023 Feb 20;23(1):23. doi: 10.1186/s12894-023-01190-0.
8
Bladder paraganglioma after kidney transplantation: A case report.肾移植后膀胱副神经节瘤:一例报告。
World J Clin Cases. 2022 Sep 6;10(25):9044-9049. doi: 10.12998/wjcc.v10.i25.9044.
9
De Novo Cancer Incidence after Kidney Transplantation in South Korea from 2002 to 2017.2002年至2017年韩国肾移植后的新发癌症发病率
J Clin Med. 2021 Aug 11;10(16):3530. doi: 10.3390/jcm10163530.
10
Malignancies after Kidney Transplantation.肾移植后的恶性肿瘤。
Clin J Am Soc Nephrol. 2022 Mar;17(3):434-443. doi: 10.2215/CJN.14570920. Epub 2021 Mar 29.
BJU Int. 2015 May;115(5):705-12. doi: 10.1111/bju.12707. Epub 2015 Jan 21.
4
Malignancy-related mortality following kidney transplantation is common.肾移植后与恶性肿瘤相关的死亡率较高。
Kidney Int. 2014 Jun;85(6):1395-403. doi: 10.1038/ki.2013.458. Epub 2013 Nov 20.
5
Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center.肝移植或肾移植受者新发恶性肿瘤发生率的比较:单中心2673例连续病例分析
Transplant Proc. 2013 Oct;45(8):3019-23. doi: 10.1016/j.transproceed.2013.08.061.
6
Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.台湾马兜铃酸相关性上尿路上皮癌:临床特征与结局。
Int J Cancer. 2013 Jul;133(1):14-20. doi: 10.1002/ijc.28013. Epub 2013 Feb 12.
7
Transitional cell carcinoma associated with aristolochic acid nephropathy: most common cancer in chronic hemodialysis patients in China.与马兜铃酸肾病相关的移行细胞癌:中国慢性血液透析患者中最常见的癌症。
Chin Med J (Engl). 2012 Dec;125(24):4460-5.
8
Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy.根治性膀胱切除术后膀胱移行细胞癌的复发模式
Acta Radiol. 2012 Oct 1;53(8):943-9. doi: 10.1258/ar.2012.110700. Epub 2012 Aug 14.
9
Malignancy after renal transplantation in the new era of immunosuppression.免疫抑制新时代下肾移植后的恶性肿瘤
Ann Transplant. 2011 Apr-Jun;16(2):14-8.
10
Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.基于人群的中药含马兜铃酸与尿路癌风险的病例对照研究。
J Natl Cancer Inst. 2010 Feb 3;102(3):179-86. doi: 10.1093/jnci/djp467. Epub 2009 Dec 21.